How much does root-canal treatment cost? Compare the quote in six parts before deciding why microscopic treatment costs more.

How much does root-canal treatment cost? What are you paying extra for in microscopic treatment?

TL;DR

Taiwan has no single national price: root-canal cost depends on the components. The extra charge for microscopic treatment reflects equipment, instruments, materials, and time; the NHI/self-pay boundary follows the NHI Administration's current notice. [F20][F24][F26][F2]

This guide is specific to Taiwan's healthcare system (National Health Insurance and Taiwan's Medical Care Act). Institutional and verification sections cite Taiwan law and competent-authority notices (geo: TW); outcome evidence for microscopy, instruments, and materials is international (geo: universal). Taiwan's Medical Care Act is the law meant throughout this guide.

Scope: cost composition only

Questions about why a tooth needs root-canal treatment, visits, or post-treatment pain belong to the basics card; crown/inlay costs belong to the crown-cost card. Commercial-insurance reimbursement depends on the policy terms; this site gives no reimbursement opinion [F30].

This card covers cost components, what microscopic-treatment add-ons buy and the strength of their evidence, and verification routes [F2]. “Microscopic” can mean non-surgical treatment under a microscope or microsurgical apical surgery; evidence from these settings is not interchangeable [F5][F14].

Cost components: split a quote into six parts

1. Examination and imaging: examination, periapical radiographs, and sometimes CBCT. The dentist decides whether imaging is indicated; ask why it is needed for this tooth [F19][F13][F2].
2. Treatment itself: tooth position, number of canals, and initial treatment versus retreatment affect workload and difficulty [F15][F12].
3. Microscopy, specialised instruments, and materials: microscope, ultrasonic instruments, bioceramic (calcium-silicate) sealer, and associated time [F4][F9][F11].
4. Temporary care and review visits: temporary sealing, medication changes, and number of visits; ask what is covered and how extra visits are charged [F2].
5. Definitive restoration: an inlay or crown is a separate item group and may explain a quote difference [F2].
6. Possible later management: ask how retreatment, apical surgery, or extraction would be charged if treatment does not succeed [F12][F13].

Microscopic-treatment add-ons: what they buy and what evidence shows

Microscope: field of view and illumination

In an observational clinical study of 312 maxillary first/second molar cases, MB2 detection was 57.4% with microscope, 55.3% with loupes, and 18.2% with no magnification; for first molars alone it was 71.1%, 62.5%, and 17.2%, with no detected microscope/loupe difference [F6]. A 2025 review/meta-analysis found missed canals associated with post-treatment apical periodontitis (85.1% versus 56.3%; OR 7.17, 95% CI 4.55 to 11.29), but had high heterogeneity and low certainty [F7].

The current 2015 Cochrane review found no eligible trial. Its wording that the effect of magnification-device type remains unknown is in the context of endodontic surgical procedures, while the finding of no eligible trial applies to the review's full scope [F4]. A 2010 review found only apical-surgery studies and no comparative study for orthograde non-surgical treatment [F5]. A 70-participant retreatment trial likewise found no magnification-device healing advantage, with low-quality evidence [F13]. A 2012 surgical meta-analysis reported 94% versus 88% (P < .0005), but it was cross-study, non-randomised and cannot support a non-surgical claim [F14]. A 2023 expert consensus says dental operating microscopes are widely used but improper use remains common when proficiency is insufficient [F8].

Ultrasonic instruments and irrigation activation

A 2024 review/meta-analysis of 3 RCTs, 474 patients (501 teeth), found passive ultrasonic versus conventional syringe irrigation had periapical-healing RR 1.10 (95% CI 1.01 to 1.21; I² = 0%) with moderate certainty; high-quality trials were limited [F9]. Surgical-retreatment evidence is inconclusive: RR 1.14 (95% CI 1.00 to 1.30; one RCT, 290 participants; low quality) [F13]. Chemical cleaning/disinfection is a crucial step, but the positive difference is small and does not mean treatment cannot be performed without this add-on [F10][F9].

Bioceramic (calcium-silicate) sealer

A 2024 review/meta-analysis of 15 comparative studies (11 RCTs, 4 prospective controlled studies), follow-up no longer than 2 years, found no significant survival/success difference between premixed bioceramic and conventional sealers; extrusion and pain differences were not significant [F11]. A 2026 review/meta-analysis of 84 studies (11,965 samples) concluded that operator experience and case selection affect success more than obturation technique; single-cone bioceramic sealers showed no clear clinical benefit, with low-to-very-low certainty [F12]. A material name is neither a price justification nor an outcome guarantee [F11][F12].

Time, difficulty, and imaging

Mandibular first-molar root/canal anatomy is highly variable across the 30 studies in a micro-CT review, one reason treatment time can differ [F15]. Initial treatment and retreatment are not the same: the 2026 review concluded overall initial-treatment success is higher, but at 6 months retreatment was higher (92.9% versus 87.1%), and only from 12 months lower [F12]. CBCT had no demonstrated healing advantage over periapical radiography in one 39-participant RCT (RR 1.02, 95% CI 0.70 to 1.47; very low quality) [F13]. The 2025 AAE/AAOMR statement is recorded only for existence/scope because full text was not retrieved [F19].

A variable absent from the quote

A Taiwan NHI database study of 517,234 initial-treatment teeth (2005 to 2011) recorded 29,219 extractions and 94.4% survival. At mean 3.43 years, survival probability was 90.3% with rubber dam and 88.8% without; adjusted extraction hazard ratio was 0.81 (95% CI 0.79 to 0.84) [F16]. Claims data do not cover self-pay treatment or clinical detail and are not an individual promise [F16].

Taiwan's system: why there is no market price

• Taiwan's Medical Care Act Article 21 assigns approval of medical-fee standards to municipal/county(city) competent authorities [F20].
• National Health Insurance Act Article 41 provides the legal procedure for payment items/standards; item coverage and conditions follow the NHI Administration's current notice. This card makes no individual coverage decision [F24][F26].
• Article 51(11) lists dentures and other non-actively-therapeutic aids as excluded; that statutory list is not a conclusion about an individual plan [F25].
• Article 22 requires an itemised receipt and forbids violation of fee standards, overcharging, or creating charge items [F21].
• Article 81 requires explanation of condition, plan, procedure, medication, prognosis, and possible adverse reactions [F22].

Four ways to verify a quote

1. Check the NHI Administration's current payment-standard notice; it provides files and says items from 114.08.11 can be downloaded from the open-data platform [F26].
2. The open-data dataset lists procedure code, NHI payment points, effective dates, English/Chinese item names, and notes, updated every 1 day. A listing is not an individual coverage decision [F27][F24].
3. For self-pay items, use the health-authority-approved standard where care is sought. The verified Taipei example is “Taipei City Dental Fee Standard for Medical Institutions” (approved 1090117), dataset 121913 [F28].
4. The NHI medical-device price-comparison site has no dentistry category; dental self-pay items cannot be checked there [F29].

Request an itemised written quote. Compare the treatment plan, quote, and receipt and ask about any mismatch [F21][F22].

Do not use another person's number as a benchmark

A 2025 Swedish decision analysis used Swedish reference prices and its 83%/93% survival thresholds; a 2026 German Markov model used German public/private fee catalogues and found perforation repair could add retention time with limited/no added cost by age [F17][F18]. Neither can be converted to Taiwan figures or conclusions; no currency amount is cited [F17][F18][F3].

Risk factors

Root-canal treatment has risks and limitations; add-ons do not eliminate them. Treatment may fail and need retreatment or surgery [F12][F13]. Missed canals are associated with post-treatment apical disease but evidence is low certainty [F7]. Perforation can occur and can require complex management to retain a tooth [F18]. Equipment alone is not an outcome criterion [F4][F8][F2]. Definitive restoration is another item group and risk set. Treatment and results vary by person and require a dentist's assessment.

Pre-visit checklist

1. Is this initial treatment or retreatment, and how do items/charges differ? [F12]
2. Which items are NHI or self-pay, and can I have an itemised written self-pay quote? [F24][F21]
3. Why is a microscope or other add-on recommended for this tooth? [F6][F7]
4. Is CBCT needed, why, and what information would be absent without it? [F13][F19]
5. How many visits are included and how are extras/medication changes charged? [F2]
6. Is definitive restoration included and when is it expected? [F2]
7. If there is no healing, how are retreatment, surgery, or extraction charged? [F12][F13]
8. Will the receipt list items/amounts, and can I cross-check it with the plan and quote? [F21][F22]

Every clinical statement in this article is mapped line by line to its cited source (see the sources and evidence chain below). It has not been clinically reviewed by a licensed practitioner. This is health information, not individual advice; assessment by a clinician is required.